secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2026-06-17T20:36:46+00:00
Accession:  0001193125-26-274258
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept resubmits NDA for relacorilant to FDA for Cushing's syndrome; six-month review expected
--------------------------------------------------------------------------------

- Resubmission based on pivotal GRACE trial and Phase III GRADIENT trial data.
- Includes additional analyses requested by FDA; expects six-month review cycle.
- Relacorilant shows durable symptom improvement without serious adverse events like hypokalemia or pregnancy termination.
- CEO states company looks forward to working with FDA toward approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000119312526274258/0001193125-26-274258-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000119312526274258/d159941d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-274258

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer